Clinical trial · Observational
The Real Life Topical Field Treatment of Actinic Keratosis Study
The Real Life Topical Field Treatment of Actinic Keratosis Study. An Observational Study Focusing on Patient Reported Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional, multinational study of topical field treatment of actinic keratosis (AK) aims to collect real-life experience with ingenol mebutate as well as one or two other topical field therapies commonly used in the individual country. Physicians will report baseline characteristics, while the main study focus will be on patient reported outcomes 3-4 weeks after treatment completion (treatment satisfaction, adherence, resource utilization and Health Related Quality of Life. Dermatology centres in Denmark, Norway, Sweden, the Netherlands, the United Kingdom and Canada will participate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-fluorouracil | Drug | Fluorouracil | ALIAS |
| Diclofenac | Drug | — | UNRESOLVED |
| Imiquimod | Drug | Imiquimod | ALIAS |
| Ingenol mebutate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Ingenol mebutate
- description
- Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
- interventionNames
- Drug: Ingenol mebutate
- label
- 5-fluorouracil
- description
- Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
- interventionNames
- Drug: 5-fluorouracil
- label
- Imiquimod
- description
- Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
- interventionNames
- Drug: Imiquimod
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients eligible to receive topical treatment with one of the following for treatment of actinic keratosis at the discretion of the dermatologist: Ingenol mebutate, 5-fluorouracil, imiquimod, diclofenac. Informed consent. \- Exclusion Criteria: Any on-going treatments at study start with ingenol mebutate, 5-fluorouracil, imiquimod or diclofenac; other topical treatment for AK in treatment area; pregnancy or planned pregnancy within treatment period. \-
References
Publications (0)
Data not yet available